152 related articles for article (PubMed ID: 8996552)
1. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
2. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
Arun B; Curti BD; Longo DL; Stevens D; Alvord WG; Gause BL; Watson T; Kopp WC; Janik JE
Cancer J Sci Am; 2000; 6(1):21-4. PubMed ID: 10696734
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
4. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia.
Barak V; Nisman B; Polliack A; Vannier E; Dinarello CA
Eur Cytokine Netw; 1998 Mar; 9(1):33-9. PubMed ID: 9613675
[TBL] [Abstract][Full Text] [Related]
5. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
Richards JM; Mick R; Latta JM; Daly K; Ratain MJ; Vardiman JW; Golomb HM
Blood; 1990 Nov; 76(10):1941-5. PubMed ID: 1700727
[TBL] [Abstract][Full Text] [Related]
10. Biological markers and minimal residual disease in hairy cell leukemia.
Lauria F; Raspadori D; Benfenati D; Rondelli D; Pallotti A; Tura S
Leukemia; 1992 Nov; 6 Suppl 4():149-51. PubMed ID: 1359204
[TBL] [Abstract][Full Text] [Related]
11. Long-term results in hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Chrobák L; Zák P; Podzimek K; Plísková L; Foglová J; Maisnar V; Dulícek P; Dĕdic K
Acta Medica (Hradec Kralove); 1997; 40(2):41-5. PubMed ID: 9389210
[TBL] [Abstract][Full Text] [Related]
12. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
Siemińska A
Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
14. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
15. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
16. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
17. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Janiec K; Wajgt A; Kondera-Anasz Z
Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
[TBL] [Abstract][Full Text] [Related]
19. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
